Curr. Oncol., Volume 31, Issue 7 (July 2024) – 43 articles
Cover Story (view full-size image):
Chimeric antigen receptor (CAR) T-cell therapy has revolutionised the treatment landscape for patients with multiple myeloma and is likely to be approved in Canada soon. Idecabtagene vicleucel (Ide-cel) (ABECMA®) and Ciltacabtagene autoleucel (Cilta-cel) (CARVYKTI®) are the two CAR T-cell therapy products for patients with relapsed or refractory multiple myeloma commercially available in the US and Europe. Although they have shown unprecedented efficacy, their clinical and logistical limitations must also be acknowledged. Therefore, it is timely that we review the latest evidence on CAR T-cell therapy in multiple myeloma, with a focus on its relevance and impact in the Canadian setting. View this paper
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Previous Issue
Next Issue
